Form 4: Avalo Therapeutics Director Vests 3,166 RSUs
Insider Transaction Report
Avalo Therapeutics Director Mitchell Chan converted 3,166 restricted stock units into common stock as part of a pre-scheduled vesting event.
Summary
- Mitchell Chan, a Director of Avalo Therapeutics, Inc. (AVTX), converted 3,166 restricted stock units (RSUs) into an equal number of common stock shares.
- This transaction occurred on March 28, 2026, and is part of a pre-scheduled vesting plan.
- The RSUs convert into common stock on a one-for-one basis.
- Following this conversion, Mitchell Chan directly holds 6,333 shares of Avalo Therapeutics Common Stock.
- An additional 3,167 restricted stock units remain beneficially owned by Mr. Chan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, reflecting a routine, pre-scheduled vesting of equity compensation for a director, with no immediate positive or negative implications for the company's operational or financial performance.
Positives
- The vesting and conversion of restricted stock units demonstrate continued alignment of director interests with shareholder value.
Negatives
- No negative aspects are indicated by this routine vesting and conversion transaction.
Risks
- No specific risks are mentioned in this Form 4 filing.
Future Outlook
The filing indicates a future vesting event for 3,167 restricted stock units on March 28, 2027, contingent on Mitchell Chan's continued service.
Industry Context
StockSavvy.ai notes that routine insider transactions like RSU vesting are common across the biotechnology and pharmaceutical industries, reflecting standard equity compensation practices for directors and executives. This particular filing does not provide broader industry insights.
Stakeholder Impact
- Shareholders: The conversion slightly increases the number of outstanding common shares, but this is a pre-planned event and generally has minimal impact. It also aligns director interests with shareholder value.
Next Steps
- The remaining 3,167 restricted stock units are scheduled to vest on March 28, 2027, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 08/13/2024 | Date Mitchell Chan was granted 9,500 restricted stock units. |
| 03/28/2025 | First vesting date for 1/3 of the granted restricted stock units. |
| 03/28/2026 | Second vesting date for 1/3 of the granted restricted stock units and the transaction date reported in this filing. |
| 03/28/2027 | Third and final vesting date for 1/3 of the granted restricted stock units. |
| 03/31/2026 | Signature date of the filing by Christopher Sullivan, Attorney-in-Fact. |
Keywords
Avalo Therapeutics, AVTX, Mitchell Chan, Form 4, SEC Filing, Restricted Stock Units, RSU Vesting, Insider Transaction, Director Ownership, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.